Molecular profiles of inflammatory myopathies
Abstract
Objective: To describe the use of large-scale gene expression profiles to distinguish broad categories of myopathy and subtypes of inflammatory myopathies (IM) and to provide insight into the pathogenesis of inclusion body myositis (IBM), polymyositis, and dermatomyositis.
Methods: Using Affymetrix GeneChip microarrays, the authors measured the simultaneous expression of approximately 10,000 genes in muscle specimens from 45 patients in four major disease categories (dystrophy, congenital myopathy, inflammatory myopathy, and normal). The authors separately analyzed gene expression in 14 patients limited to the three major subtypes of IM. Bioinformatics techniques were used to classify specimens with similar expression profiles based on global patterns of gene expression and to identify genes with significant differential gene expression compared with normal.
Results: Ten of 11 patients with IM, all normals and nemaline myopathies, and 10 of 12 patients with Duchenne muscular dystrophy were correctly classified by this approach. The various subtypes of inflammatory myopathies have distinct gene expression signatures. Specific sets of immune-related genes allow for molecular classification of patients with IBM, polymyositis, and dermatomyositis. Analysis of differential gene expression identifies as relevant to disease pathogenesis previously reported cytokines, major histocompatibility complex class I and II molecules, granzymes, and adhesion molecules, as well as newly identified members of these categories. Increased expression of actin cytoskeleton genes is also identified.
Conclusions: The molecular profiles of muscle tissue in patients with inflammatory myopathies are distinct and represent molecular signatures from which diagnostic insight may follow. Large numbers of differentially expressed genes are rapidly identified.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin . 1997; 15: 615–648.
2.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol . 1995; 38: 705–713.
3.
Pruitt JN II, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol . 1996; 39: 139–143.
4.
Barohn RJ. The therapeutic dilemma of inclusion body myositis. Neurology . 1997; 48: 567–568.
5.
Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to therapy. Neurology . 1995; 45: 1302–1304.
6.
Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol . 1996; 40: 581–586.
7.
Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: observations in 40 patients. Brain . 1989; 112: 727–747.
8.
Dalakas MC. Progress in inflammatory myopathies: good but not good enough. J Neurol Neurosurg Psychiatry . 2001; 70: 569–573.
9.
Blume G, Pestronk A, Frank B, Johns DR. Polymyositis with cytochrome oxidase negative muscle fibres: early quadriceps weakness and poor response to immunosuppressive therapy. Brain . 1997; 120: 39–45.
10.
Levine TD, Pestronk A. Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment. Muscle Nerve . 1998; 21: 1724–1728.
11.
Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. Ann Neurol . 1996; 40: 782–791.
12.
Munsat TL, Piper D, Cancilla P, Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology . 1972; 22: 335–347.
13.
McNally EM, Ly CT, Rosenmann H, et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet . 2000; 91: 305–312.
14.
Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med . 1993; 94: 379–387.
15.
Carpenter S, Karpati G. Pathology of skeletal muscle, 2nd ed. New York: Oxford University Press, 2001.
16.
Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol . 1990; 27: 343–56.
17.
Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med . 1986; 314: 329–334.
18.
Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol . 1991; 48: 26–30.
19.
Greenberg SA. DNA microarray technology and its application to neurological disorders. Neurology . 2001; 57: 755–761.
20.
Alizadeh A, Eisen M, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature . 2000; 403: 503–511.
21.
Alon U, Barkai N, Notterman DA, et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A . 1999; 96: 6745–6750.
22.
Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science . 1999; 286: 531–537.
23.
Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature . 2000; 406: 536–540.
24.
Watson MA, Perry A, Budhjara V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res . 2001; 61: 1825–1829.
25.
Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med . 2001; 344: 539–548.
26.
Roses AD. Pharmacogenetics and the practice of medicine. Nature . 2000; 405: 857–865.
27.
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science . 1999; 286: 487–491.
28.
Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet . 1999; 21: 48–50.
29.
Marton M, DeRisi J, Bennett H, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med . 1998; 4: 1293–1301.
30.
Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet . 1999; 21 (suppl 1): 33–37.
31.
Affymetrix GeneChip Analysis Suite User Guide, Version 3.3, 1999.
32.
Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA . 1998; 95: 14863–14868.
33.
The Human Gene Nomenclature Committee. Available at http://www.gene.ucl.ac.uk/nomenclature.
34.
CHIP bioinformatics tools. Available at http://bio.chip.org:8080/bio/unchip.
35.
Basic Local Alignment Search Tool. Available at http://ncbi.nlm.nih.gov./
36.
Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501(+) children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol . 2002; 168: 4154–4163.
37.
Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry . 2000; 68: 472–478.
38.
Bartoccioni E, Gallucci S, Scuderi F, et al. MHC class I, MHC class II, and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol . 1994; 95: 166–172.
39.
Wiendl H, Behrens L, Maier S, et al. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol . 2000; 48: 679–684.
40.
Englund P, Lindroos E, Nennesmo I, et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol . 2001; 159: 1263–1273.
41.
Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol . 1995; 37 (suppl 1): S74–S86.
42.
Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol . 1996; 55: 342–347.
43.
De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol . 1994; 53: 369–376.
44.
Choi Y, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology . 2000; 54: 65–71.
45.
Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol . 1998; 55: 1509–1512.
46.
Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, dystrophy, and non-weak controls. J Neuroimmunol . 1995; 63: 9–16.
47.
Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol . 1986; 19: 112–125.
48.
Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. Beta-amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport . 1993; 4: 815–818.
49.
Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol . 1994; 144: 177–187.
50.
Askanas V, Serdaroglu P, Engel WK, Alvarez RB. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology . 1992; 42: 460–461.
51.
Sarkozi E, Askanas V, Engel WK. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol . 1994; 145: 1280–1284.
52.
Bilak M, Askanas V, Engel WK. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Acta Neuropathol (Berl) . 1993; 85: 378–382.
53.
Mirabella M, Alvarez RB, Engel WK, Weisgraber KH, Askanas V. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies. Ann Neurol . 1996; 40: 864–872.
54.
Askanas V, Sarkozi E, Alvarez RB, McFerrin J, Siddique T, Engel WK. SOD1 gene and protein in vacuolated muscle fibers of s-IBM, h-IBM, and in cultured human muscle after bAPP gene transfer. Neurology . 1996; 46: 487.
55.
Tsuruta Y, Furuta A, Taniguchi N, Yamada T, Kira J, Iwaki T. Increased expression of manganese superoxide dismutase is associated with that of nitrotyrosine in myopathies with rimmed vacuoles. Acta Neuropathol (Berl) . 2002; 103: 59–65.
56.
Prayson RA, Yu AC. Bcl-2, Bcl-x, and Bax expression by immunohistochemistry in inclusion body myositis: a study of 27 cases. Arch Pathol Lab Med . 2001; 125: 1326–1330.
57.
Jaworska-Wilczynska M, Wilczynski GM, Engel WK, Strickland DK, Weisgraber KH, Askanas V. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology . 2002; 58: 438–445.
58.
Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol . 1998; 29: 1128–1133.
59.
Askanas V, Sarkozi E, Bilak M, Alvarez RB, Engel WK. Human muscle macrophages express beta-amyloid precursor and prion proteins and their mRNAs. Neuroreport. 1995; 6: 1045–1049.
60.
Amato AA, Shebert RT. Inclusion body myositis in twins. Neurology. 1998; 51: 598–600.
61.
Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in three families. Brain. 1997; 120: 653–661.
62.
Sivakumar K, Dalakas MC. The spectrum of familial inclusion body myopathies in 13 families and a description of a quadriceps-sparing phenotype in non-Iranian Jews. Neurology. 1996; 47: 977–984.
63.
The National Center for Biotechnology Information, GenBank. Available at http://www.ncbi.nlm.nih.gov/UniGene./
64.
Affymetrix Inc. Available at http://www.affymetrix.com/products/gc_U133.html. Accessed on 1/05/02.
65.
Hughes TR, Mao M, Jones AR, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol . 2001; 19: 342–347.
Information & Authors
Information
Published In
Copyright
© 2002.
Publication History
Received: March 6, 2002
Accepted: July 5, 2002
Published online: October 22, 2002
Published in print: October 22, 2002
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Recent Updates on the Pathogenesis of Inflammatory Myopathies, Current Rheumatology Reports, 26, 12, (421-430), (2024).https://doi.org/10.1007/s11926-024-01164-7
- The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties, ImmunoHorizons, 7, 5, (310-322), (2023).https://doi.org/10.4049/immunohorizons.2200078
- Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy, Cells, 12, 17, (2198), (2023).https://doi.org/10.3390/cells12172198
- Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease, Indian Journal of Dermatology, Venereology and Leprology, 90, (30-40), (2023).https://doi.org/10.25259/IJDVL_15_2023
- Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis, Neurology, 98, 21, (e2108-e2119), (2022)./doi/10.1212/WNL.0000000000200271
- Construction and validation of a ferroptosis-related long noncoding RNA signature in clear cell renal cell carcinoma, Cancer Cell International, 22, 1, (2022).https://doi.org/10.1186/s12935-022-02700-0
- NLRP3 inflammasome up-regulates major histocompatibility complex class I expression and promotes inflammatory infiltration in polymyositis, BMC Immunology, 23, 1, (2022).https://doi.org/10.1186/s12865-022-00515-2
- Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis, Journal of Neurology, 269, 8, (4161-4173), (2022).https://doi.org/10.1007/s00415-022-11029-7
- Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis, Annals of Neurology, 91, 3, (317-328), (2022).https://doi.org/10.1002/ana.26304
- Apremilast in Recalcitrant Cutaneous Dermatomyositis, JAMA Dermatology, 158, 12, (1357), (2022).https://doi.org/10.1001/jamadermatol.2022.3917
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.